Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021

 Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021

Shots:

  • The P-Ib/II CodeBreaK 101 study evaluates Lumakras + Vectibix in 31 patients with KRAS G12C-mutated advanced CRC
  • The results demonstrated ORR (27%) among 26 patients in the efficacy analysis, DCR (81%), 33% of patients experienced a response in the expansion cohort, no patients experienced dose-limiting toxicities during the 28 days following initial treatment. The therapy also demonstrated the efficacy and safety
  • Amgen has completed an enrolment in P-III CodeBreaK 200 trial to evaluate sotorasib vs docetaxel in patients with KRAS G12C-mutated NSCLC. Lumakras is also being studied in multiple other solid tumors

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post